Please assess the completion status of the following clinical trial:

Trial Title: Improving Neurological Outcome for Acute Basilar Artery Occlusion With Sufficient Recanalization After Thrombectomy by Intraarterial Tenecteplase (INSIST-IT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18~* Patients with basilar artery occlusion who received endovascular treatment within 24 hours of estimated time of stroke onset as per BASICS trial definition;~* National Institute of Health Stroke Scale (NIHSS) ≥ 6 before endovascular treatment;~* Successful recanalization (mTICI 2b-3) after endovascular treatment;~* PC-ASPECTS ≥ 6 on CT;~* Absence of parenchymal hematoma on CT images done in the angio suite immediately after the procedure;~* Modified Rankin Scale score before stroke onset ≤ 3;~* Signed informed consent by patient or their legally authorized representative.~Exclusion Criteria:~* baseline PC ASPECTS \< 5 on CT;~* More than six retrieval attempts in the same vessel;~* Hemorrhagic stroke: cerebral hemorrhage, subarachnoid hemorrhage;~* Coagulation disorders, systemic hemorrhagic diathesis, thrombocytopenia (\<100000/mm3), or INR \> 1.7;~* Severe hepatic or renal dysfunction, increase in ALT or AST (more than 2 times of upper limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis;~* After recanalization, severe and sustained (i.e., \> 5 minutes) uncontrolled hypertension (systolic blood pressure over 180mmHg or diastolic blood pressure over 105 mmHg) refractory to antihypertensive medication;~* Patients with contraindication or allergic to any ingredient of drugs in our study~* Pregnancy, plan to get pregnant or during lactation~* The estimated life expectancy is less than 6 months due to other serious diseases;~* Other conditions unsuitable for this clinical study assessed by researcher.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TNK group (Type: EXPERIMENTAL): None
- control group (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).